
Opinion|Videos|May 7, 2025
Exploring the Impact of Bronchiectasis Exacerbations
Panelists discuss how bacterial infections, environmental triggers, and microbiome imbalances cause bronchiectasis exacerbations, leading to increased cough, phlegm, fatigue, and hemoptysis.
Advertisement
Episodes in this series

Clinical Brief: Causes and Management of Bronchiectasis Exacerbations
Main Discussion Topics
- Exacerbations are commonly triggered by bacterial infections, viral etiologies, and environmental factors.
- Impaired mucosal clearance significantly contributes to recurrent exacerbations.
- Management approaches include multiple modalities targeting different aspects of the disease.
Key Points for Physicians
- Monitor for increased cough, phlegm, fatigue, and hemoptysis as signs of exacerbation.
- Treatment options include:
- Oral, intravenous, or inhaled antibiotics based on severity
- Airway clearance devices (Vest, oscillating positive expiratory pressure devices like AerobikA/Acapella)
- Breathing techniques and mechanical assistance
- Anti-inflammatory approaches (DPP1 inhibitors, inhaled corticosteroids for eosinophilic phenotype)
- Consider surgical intervention for refractory cases
Notable Insights
Comprehensive management must address multiple dimensions, including infection control, inflammation reduction, mucus clearance enhancement, and hydration.
Clinical Significance
Effective bronchiectasis exacerbation management requires targeted multimodal therapies addressing both immediate symptoms and underlying mechanisms to prevent recurrence.
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

FDA approved adrabetadex for infantile-onset Niemann-Pick disease type C after survival data showed 84% vs 42% 5-year survival with treatment.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
2
Complicated UTI Care Strained by Unclear Goals, Access Gaps
3
Obesity Care Ownership Shifts to Specialties That Win Coverage
4
Emerging Threats to Cell and Gene Therapy Access
5

